~~<i id='60B30E43D4'><strike id='60B30E43D4'><tt id='60B30E43D4'><pre id='60B30E43D4'></pre></tt></strike></i>~~

Home» Wikipedia» focus

focus

author：fashion 2025-09-06 08:28:10 Page View：8

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Woodcock on FDA’s accelerated approval and her next chapter
Next article： Heart attack and stroke risk calculators need revising

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

FDA drug safety: Singulair case shows systemic surveillance flaws

AdobeAfteradrugentersthemarket,it’suptoFoodandDrugAdministrationregulatorstoensureitscontinuedsafety

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

DarronCummings/APLONDON—AU.K.governmentagencyonTuesdaysaidthatitwon’trecommendEliLilly’sMounjaro—par

WSS

focus

focus

leisure time

explore

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes